tirzepatide vs ozempic which is safer vs. Semaglutide: What You Should Know Ozempic vs Mounjaro What's the

Z.ZhaoY.ZhangY.et al (2023)

In adults with obesity or overweight with 1 weight-related comorbidity, along with diet and exercise, A well-studied safety profile: Pooled safety data from 3 weight-management clinical trials evaluating Wegovy 2.4 mg pen 1 6.8% of patients treated with Wegovy and 3.2% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions 1 Permanent discontinuation of treatment as a result of a gastrointestinal adverse reaction occurred in 4.3% of patients treated with Wegovy vs 0.7% of patients treated with placebo 1 The most common adverse reactions leading to discontinuation were: Nausea (1.8% vs 0.2%) , vomiting (1.2% vs 0%) , and diarrhea (0.7% vs 0.1%) for Wegovy and placebo, respectively 2 *Includes abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain, abdominal tenderness, abdominal discomfort, and epigastric discomfort

The GH increases in women were slightly lower, equal to +70% for GH AUC and a 27% increase in IGF-1 levels

Semaglutide is a medication classified as a GLP-1 receptor agonist

Use rapid-acting insulin or modify basal doses according to clinical discretion and close monitoring

GLP-1 receptor agonists, such as semaglutide (Wegovy), have emerged as effective tools for achieving and maintaining weight loss in this demographic